share_log

オンコリスバイオファーマ:免疫療法難治性食道胃腺がんで、治験責任医師が開始したペムブロリズマブのOBP-301の第2相臨床試験に最初に登録された患者

Oncolys BioPharma: Patients with esophageal gastric adenocarcinoma refractory to immunotherapy who were first enrolled in the OBP-301 phase 2 clinical trial of pembrolizumab initiated by the investigator responsible physician

JPX ·  Jun 3 02:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more